Perspective for Prophylaxis and Treatment of Cervical Cancer: An Immunological Approach

References

• Brinkman JA, Caffrey AS, Muderspach LI, The impact of anti HPV vaccination on cervical cancer incidence and HPV induced cervical lesions: consequences for clinical management. Eur J Gynaecol Oncol. 2005; 26:129–142.
   PubMed Web of Science ®Google Scholar
• Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med. 2008; 359:821–832.
   PubMed Web of Science ®Google Scholar
• Kahn JA. HPV vaccination for the prevention of cervical intraepithelial neoplasia. N Engl J Med. 2009; 361:271–278.
   PubMed Web of Science ®Google Scholar
• Gershenson DM. Gynecologic Cancer: Controversies in Management. Philadelphia, PA: Elserver; 2004.
   Google Scholar
• Hoskins WJ. Principles and Practive of Gynecologic Oncology, 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005.
   Google Scholar
• Beller U, Abu-Rustum NR. Cervical cancers after human papillomavirus vaccination. Obstet Gynecol. 2009; 113:550–552.
   PubMedGoogle Scholar
• Franco EL, Schlecht NF, Saslow D. The epidemiology of cervical cancer. Cancer J. 2003; 9:348–359.
   PubMed Web of Science ®Google Scholar
• Insinga RP, Dasbach EJ, Elbasha EH. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature. Pharmacoeconomics. 2005; 23:1107–1122.
   PubMedGoogle Scholar
• Huh WK. Human papillomavirus infection: a concise review of natural history. Obstet Gynecol. 2009; 114:139–143.
   PubMedGoogle Scholar
• Whiteside MA, Siegel EM, Unger ER. Human papillomavirus and molecular considerations for cancer risk. Cancer. 2008; 113:2981–2994.
   PubMedGoogle Scholar
• Peters WA 3rd, Liu PY, Barrett RJ 2nd, Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000; 18:1606–1613.
   PubMed Web of Science ®Google Scholar
• Sedlis A, Bundy BN, Rotman MZ, A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a Gynecologic Oncology Group Study. Gynecol Oncol. 1999; 73:177–183.
   PubMed Web of Science ®Google Scholar
• Morris M, Eifel PJ, Lu J, Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999; 340:1137–1143.
   PubMed Web of Science ®Google Scholar
• Whitney CW, Sause W, Bundy BN, Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999; 17:1339–1348.
   PubMed Web of Science ®Google Scholar
• Rose PG, Bundy BN, Watkins EB, Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999; 340:1144–1153.
   PubMed Web of Science ®Google Scholar
• Roman LD, Felix JC, Muderspach LI, Risk of residual invasive disease in women with microinvasive squamous cancer in a conization specimen. Obstet Gynecol. 1997; 90:759–764.
   PubMed Web of Science ®Google Scholar
• Creasman WT, Zaino RJ, Major FJ, Early invasive carcinoma of the cervix (3 to 5 mm invasion): risk factors and prognosis: a Gynecologic Oncology Group study. Am J Obstet Gynecol. 1998; 178:62–65.
   PubMedGoogle Scholar
• Burnett AF, Roman LD, O'Meara AT, Radical vaginal trachelectomy and pelvic lymphadenectomy for preservation of fertility in early cervical carcinoma. Gynecol Oncol. 2003; 88:419–423.
   PubMedGoogle Scholar
• Landoni F, Maneo A, Colombo A, Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet. 1997; 350:535–540.
   PubMed Web of Science ®Google Scholar
• Long HJ 3rd, Monk BJ, Huang HQ, Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 2006; 100:537–543.
   PubMed Web of Science ®Google Scholar
• Long HJ 3rd, Bundy BN, Grendys EC Jr, Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol. 2005; 23:4626–4633.
   PubMed Web of Science ®Google Scholar
• Dehn D, Torkko KC, Shroyer KR. Human papillomavirus testing and molecular markers of cervical dysplasia and carcinoma. Cancer. 2007; 111:1–14.
   PubMed Web of Science ®Google Scholar
• Holladay EB, Logan S, Arnold J, A comparison of the clinical utility of p16(INK4a) immunolocalization with the presence of human papillomavirus by hybrid capture 2 for the detection of cervical dysplasia/neoplasia. Cancer. 2006; 108:451–461.
   PubMedGoogle Scholar
• Dillner J, Rebolj M, Birembaut P, Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ. 2008; 337:a1754.
   PubMed Web of Science ®Google Scholar
• Cuzick J, Arbyn M, Sankaranarayanan R, Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine. 2008; 19:K29-K41.
   Google Scholar
• Schiffman M, Castle PE, Jeronimo J, Human papillomavirus and cervical cancer. Lancet. 2007; 370:890–907.
   PubMed Web of Science ®Google Scholar
• Wright TC Jr, Schiffman M. Adding a test for human papillomavirus DNA to cervical-cancer screening. N Engl J Med. 2003; 348:489–490.
   PubMed Web of Science ®Google Scholar
• Rowhani-Rahbar A, Mao C, Hughes JP, Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine. 2009; 27:5612–5619.
   PubMed Web of Science ®Google Scholar
• Ronco G, Segnan N, Giorgi-Rossi P, Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst. 2006; 98:765–774.
   PubMed Web of Science ®Google Scholar
• Hildesheim A, Herrero R. Human papillomavirus vaccine should be given before sexual debut for maximum benefit. J Infect Dis. 2007 Nov 15;196(10):1431–1432. Epub 2007 Oct 31.
   PubMedGoogle Scholar
• Schwarz TF, Spaczynski M, Schneider A, Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15–55 years. Vaccine. 2009; 27:581–587.
   PubMed Web of Science ®Google Scholar
• Munoz N, Manalastas R, Jr., Pitisuttithum P, Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet. 2009; 373:1949–1957.
   PubMed Web of Science ®Google Scholar
• Paavonen J, Naud P, Salmeron J, Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009; 374:301–314.
   PubMed Web of Science ®Google Scholar
• Romanowski B, de Borba PC, Naud PS, Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet. 2009; 374:1975–1985.
   PubMed Web of Science ®Google Scholar
• Koulova A, Tsui J, Irwin K, Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006-January 2008. Vaccine. 2008; 26:6529–6541.
   PubMed Web of Science ®Google Scholar
• Agosti JM, Goldie SJ. Introducing HPV vaccine in developing countries—key challenges and issues. N Engl J Med. 2007; 356:1908–1910.
   PubMed Web of Science ®Google Scholar
• Garcia-Sicilia J, Schwarz TF, Carmona A, Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine coadministered with combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine to girls and young women. J Adolesc Health. 2010; 46:142–151.
   PubMed Web of Science ®Google Scholar
• Garland SM, Hernandez-Avila M, Wheeler CM, Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007; 356:1928–1943.
   PubMed Web of Science ®Google Scholar
• Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007; 356:1915–1927.
   PubMed Web of Science ®Google Scholar
• Wheeler CM, Kjaer SK, Sigurdsson K, The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis. 2009; 199:936–944.
   PubMed Web of Science ®Google Scholar
• Brown DR, Kjaer SK, Sigurdsson K, The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16–26 years. J Infect Dis. 2009; 199:926–935.
   PubMed Web of Science ®Google Scholar
• Munoz N, Kjaer SK, Sigurdsson K, Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst. 2010; 102:325–339.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Product approval-prescribing information [package insert] Gardasil® [human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant], Merck and Co, Inc: Food and Drug Administration. 2009. Available from www.fda.gov /BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM094042.
   Google Scholar
• Merck USA. Highlights of prescribing information: GARDASIL® [human papillomavirus quadrivalent (Types 6, 11, 16, and 18) vaccine, Recombinant] 2008. Available from www.merck.com /product/usa/pi_circulars/g/Gardasil®_pi.pdf.
   Google Scholar
• Human papillomavirus vaccines. WHO position paper. Wkly Epidemiol Rec. 2009; 84:118–131.
   PubMedGoogle Scholar
• Mariani L, Venuti A. HPV vaccine: an overview of immune response, clinical protection, and new approaches for the future. J Transl Med. 2010; 8:105.
   PubMed Web of Science ®Google Scholar
• Olsson SE, Villa LL, Costa RL, Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine. 2007; 25:4931–4939.
   PubMed Web of Science ®Google Scholar
• Ault KA. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet. 2007; 369:1861–1868.
   PubMed Web of Science ®Google Scholar
• Policy statement: Recommended childhood and adolescent immunization schedules—United States, 2010. Pediatrics. 2010; 125:195–196.
   PubMed Web of Science ®Google Scholar
• Friedman LS, Kahn J, Middleman AB, Human papillomavirus (HPV) vaccine: a position statement of the Society for Adolescent Medicine. J Adolesc Health. 2006 Oct;39(4):620.
   PubMed Web of Science ®Google Scholar
• Pedersen C, Petaja T, Strauss G, Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health. 2007; 40:564–571.
   PubMed Web of Science ®Google Scholar
• Paavonen J, Jenkins D, Bosch FX, Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007; 369:2161–2170.
   PubMed Web of Science ®Google Scholar
• Villa LL, Costa RL, Petta CA, High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006; 95:1459–1466.
   PubMed Web of Science ®Google Scholar
• McKeage K, Romanowski B. AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix(R)): a review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types. Drugs. 2011; 71:465–488.
   PubMed Web of Science ®Google Scholar
• Fraser C, Tomassini JE, Xi L, Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. Vaccine. 2007; 25:4324–4333.
   PubMed Web of Science ®Google Scholar
• Kim JJ, Andres-Beck B, Goldie SJ. The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. Br J Cancer. 2007; 97:1322–1328.
   PubMed Web of Science ®Google Scholar
• Techakehakij W, Feldman RD. Cost-effectiveness of HPV vaccination compared with Pap smear screening on a national scale: a literature review. Vaccine. 2008; 26:6258–6265.
   PubMed Web of Science ®Google Scholar
• Kanodia S, Da Silva DM, Kast WM. Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions. Int J Cancer. 2008; 122:247–259.
   Google Scholar
• Sewell DA, Pan ZK, Paterson Y. Listeria-based HPV-16 E7 vaccines limit autochthonous tumor growth in a transgenic mouse model for HPV-16 transformed tumors. Vaccine. 2008; 26:5315–5320.
   PubMed Web of Science ®Google Scholar
• Bermudez-Humaran LG, Cortes-Perez NG, Le Loir Y, An inducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci. J Med Microbiol. 2004; 53:427–433.
   PubMed Web of Science ®Google Scholar
• Cortes-Perez NG, Azevedo V, Alcocer-Gonzalez JM, Cell-surface display of E7 antigen from human papillomavirus type-16 in Lactococcus lactis and in Lactobacillus plantarum using a new cell-wall anchor from lactobacilli. J Drug Target. 2005; 13:89–98.
   PubMed Web of Science ®Google Scholar
• Peters C, Paterson Y. Enhancing the immunogenicity of bioengineered Listeria monocytogenes by passaging through live animal hosts. Vaccine. 2003; 21:1187–1194.
   PubMed Web of Science ®Google Scholar
• Maciag PC, Radulovic S, Rothman J. The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix. Vaccine. 2009; 27:3975–3983.
   PubMed Web of Science ®Google Scholar
• Kaufmann AM, Stern PL, Rankin EM, Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res. 2002; 8:3676–3685.
   PubMed Web of Science ®Google Scholar
• Baez-Astua A, Herraez-Hernandez E, Garbi N, Low-dose adenovirus vaccine encoding chimeric hepatitis B virus surface antigen-human papillomavirus type 16 E7 proteins induces enhanced E7-specific antibody and cytotoxic T-cell responses. J Virol. 2005; 79:12807–12817.
   PubMed Web of Science ®Google Scholar
• Santin AD, Bellone S, Roman JJ, Therapeutic vaccines for cervical cancer: dendritic cell-based immunotherapy. Curr Pharm Des. 2005; 11:3485–3500.
   PubMed Web of Science ®Google Scholar
• Santin AD, Bellone S, Palmieri M, HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. Gynecol Oncol. 2006; 100:469–478.
   PubMed Web of Science ®Google Scholar
• Tsen SW, Paik AH, Hung CF, Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells. Expert Rev Vaccines. 2007; 6:227–239.
   PubMed Web of Science ®Google Scholar
• Hung CF, Wu TC. Improving DNA vaccine potency via modification of professional antigen presenting cells. Curr Opin Mol Ther. 2003; 5:20–24.
   PubMed Web of Science ®Google Scholar
• Lu D, Hoory T, Monie A, Treatment with demethylating agent, 5-aza-2′-deoxycytidine enhances therapeutic HPV DNA vaccine potency. Vaccine. 2009; 27:4363–4369.
   PubMed Web of Science ®Google Scholar
• Smahel M, Polakova I, Pokorna D, Enhancement of T cell-mediated and humoral immunity of beta-glucuronidase-based DNA vaccines against HPV16 E7 oncoprotein. Int J Oncol. 2008; 33:93–101.
   PubMed Web of Science ®Google Scholar
• Massa S, Simeone P, Muller A, Antitumor activity of DNA vaccines based on the human papillomavirus-16 E7 protein genetically fused to a plant virus coat protein. Hum Gene Ther. 2008; 19:354–364.
   PubMed Web of Science ®Google Scholar
• Kim TW, Hung CF, Boyd D, Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life with intracellular targeting strategies. J Immunol. 2003; 171:2970–2976.
   PubMed Web of Science ®Google Scholar
• Kim TW, Lee JH, He L, Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency. Cancer Res. 2005; 65:309–316.
   PubMed Web of Science ®Google Scholar
• Sheets EE, Urban RG, Crum CP, Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA. Am J Obstet Gynecol. 2003; 188:916–926.
   PubMed Web of Science ®Google Scholar
• Trimble CL, Peng S, Kos F, A phase I trial of a human papillomavirus DNA vaccine for HPV16 +cervical intraepithelial neoplasia 2/3. Clin Cancer Res. 2009; 15:361–367.
   PubMed Web of Science ®Google Scholar
• Yue FY, Dummer R, Geertsen R, Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. Int J Cancer. 1997; 71:630–637.
   PubMed Web of Science ®Google Scholar
• Gorelik L, Flavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med. 2001; 7:1118–1122.
   PubMed Web of Science ®Google Scholar
• Munn DH, Mellor AL. IDO and tolerance to tumors. Trends Mol Med. 2004; 10:15–18.
   PubMed Web of Science ®Google Scholar
• Rubinstein N, Alvarez M, Zwirner NW, Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection: a potential mechanism of tumor-immune privilege. Cancer Cell. 2004; 5:241–251.
   PubMed Web of Science ®Google Scholar
• Goldberg MV, Maris CH, Hipkiss EL, Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. Blood. 2007; 110:186–192.
   PubMed Web of Science ®Google Scholar
• Kim R, Emi M, Tanabe K, Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res. 2006; 66:5527–5536.
   PubMed Web of Science ®Google Scholar
• Kanodia S, Da Silva DM, Karamanukyan T, Expression of LIGHT/TNFSF14 combined with vaccination against human papillomavirus type 16 E7 induces significant tumor regression. Cancer Res. 2010; 70:3955–3964.
   PubMedGoogle Scholar
• Fahey LM, Raff AB, Da Silva DM, Reversal of human papillomavirus-specific T cell immune suppression through TLR agonist treatment of Langerhans cells exposed to human papillomavirus type 16. J Immunol. 2009; 182:2919–2928.
   PubMed Web of Science ®Google Scholar
• Karanam B, Jagu S, Huh WK, Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection. Immunol Cell Biol. 2009; 87:287–299.
   PubMed Web of Science ®Google Scholar
• Jagu S, Karanam B, Gambhira R, Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J Natl Cancer Inst. 2009; 101:782–792.
   PubMed Web of Science ®Google Scholar
• Melief CJ. Synthetic vaccine for the treatment of lesions caused by high risk human papilloma virus. Cancer J. 2011; 17:300–301.
   PubMedGoogle Scholar
• Kreimer AR, Clifford GM, Boyle P, Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005; 14:467–475.
   PubMed Web of Science ®Google Scholar
• Ryan DP, Mayer RJ. Anal carcinoma: histology, staging, epidemiology, treatment. Curr Opin Oncol. 2000; 12:345–352.
   PubMedGoogle Scholar
• Chin-Hong PV, Husnik M, Cranston RD, Anal human papillomavirus infection is associated with HIV acquisition in men who have sex with men. AIDS. 2009; 23:1135–1142.
   PubMed Web of Science ®Google Scholar
• Winer RL, Hughes JP, Feng Q, Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med. 2006; 354:2645–2654.
   PubMed Web of Science ®Google Scholar
• Hernandez BY, Wilkens LR, Zhu X, Transmission of human papillomavirus in heterosexual couples. Emerg Infect Dis. 2008; 14:888–894.
   PubMed Web of Science ®Google Scholar
• Baldwin SB, Wallace DR, Papenfuss MR, Condom use and other factors affecting penile human papillomavirus detection in men attending a sexually transmitted disease clinic. Sex Transm Dis. 2004; 31:601–607.
   PubMed Web of Science ®Google Scholar
• Bleeker MC, Heideman DA, Snijders PJ, Penile cancer: epidemiology, pathogenesis and prevention. World J Urol. 2009; 27:141–150.
   PubMed Web of Science ®Google Scholar
• Bleeker MC, Hogewoning CJ, Van Den Brule AJ, Penile lesions and human papillomavirus in male sexual partners of women with cervical intraepithelial neoplasia. J Am Acad Dermatol. 2002; 47:351–357.
   PubMedGoogle Scholar
• Giuliano A, Palefsky J. The efficacy of the quadrivalent HPV (types 6/11/16/18) vaccine in reducing the incidence of HPV-related genital disease in young men. In: Proceedings from the European Research Organization on Genital Infection and Neoplasia Congress, November 12–15, 2008. Nice, France: Acropolis. Abstract SS 19-7a.
   Google Scholar